Sierra Oncology Inc
Change company Symbol lookup
Select an option...
SRRA Sierra Oncology Inc
ICPT Intercept Pharmaceuticals Inc
MO Altria Group Inc
AI Inc
INUV Inuvo Inc
PZZA Papa John's International Inc
REVHU Revolution Healthcare Acquisition Corp
DORM Dorman Products Inc
MDT Medtronic PLC
BA Boeing Co

Health Care : Biotechnology | Small Cap Value
Based in Canada
Company profile

Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).

Day's Change
0.03 (0.05%)
B/A Size
Day's High
Day's Low

Today's volume of 18,364 shares is on pace to be much lighter than SRRA's 10-day average volume of 251,849 shares.


Fiserv Inc. Stock Outperforms Competitors Despite Losses On The Day

4:54 pm ET January 10, 2022 (MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Fiserv Inc. (FISV) slid 0.99% to $107.75 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.14% to 4,670.29 and Dow Jones Industrial Average falling 0.45% to 36,068.87. This was the stock's second consecutive day of losses. Fiserv Inc. closed $19.59 short of its 52-week high ($127.34), which the company reached on April 26th.

Despite its losses, the stock outperformed some of its competitors Monday, as Visa Inc. Cl A (V) fell 2.30% to $211.97, Mastercard Inc. (MA) fell 1.55% to $363.91, and Fidelity National Information Services Inc. (FIS) fell 1.08% to $116.37.true Trading volume (3.7 M) remained 849,296 below its 50-day average volume of 4.5 M.

Data source: Dow Jones Market Data, FactSet. Data compiled Janurary 10, 2022.

-MarketWatch Automation


(END) Dow Jones Newswires

January 10, 2022 16:54 ET (21:54 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.